The Different Faces of Chronic Lymphocytic Leukemia -Two Clinical Cases

1. Barrientos JC. Management of Chronic Lymphocytic Leukemia in the Elderly. Cancer Control 2015 Oct; 22(4 Suppl): 17-23.10.1177/107327481502204s04476359926618342Search in Google Scholar

2. Jain N, O’Brien S. Initial treatment of CLL: integrating biology and functional status. Blood 2015; 126(4): 463-70.10.1182/blood-2015-04-585067462444126065656Search in Google Scholar

3. Mozas P, Rivas-Delgado A, Baumann T, et al. Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia. Blood Cancer J. 2018; 8(1): 1-5.10.1038/s41408-017-0044-5580253329339727Search in Google Scholar

4. Oscier D, Dearden C, Eren E, Fegan C, et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol. 2012; 59: 541-64.10.1111/bjh.1206723057493Search in Google Scholar

5. Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26(suppl_5): 78-84.10.1093/annonc/mdv30326314781Search in Google Scholar

6. Bond AD, Huang Y, Fisher LJ, et al. Second cancer incidence in CLL patients receiving BTK inhibitors. J Clin Oncol. 2019; 37, (15): 7511-7511.Search in Google Scholar

7. Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US intergroup phase III trial E2997. J ClinOncol. 2007; 25(7): 799-804.10.1200/JCO.2006.08.308917283363Search in Google Scholar

8. Raedler AL. Imbruvica (Ibrutinib) Now FDA Approved as First-Line Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. Eighth Annual Payers’ Guide -Select Drug Profiles, Payers’ Guide March 2017, Vol 10.Search in Google Scholar

9. Parmar S, Patel K, Pinilla-Ibarz J. Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. P T. 2014 Jul; 39(7): 483-519.Search in Google Scholar

10. Brown JR. How I treat CLL patients with ibrutinib. Blood 2018; 131(4): 379-86.10.1182/blood-2017-08-76471229255067Search in Google Scholar

11. Puiggros A, Blanco G, Espinet B. Genetic Abnormalities in Chronic Lymphocytic Leukemia:Where We Are and Where We Go. Biomed Res Int. 2014.10.1155/2014/435983405468024967369Search in Google Scholar

12. Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA,et al. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood 2018; 132(21): 2249-59.10.1182/blood-2018-06-860593625100930254130Search in Google Scholar